Urinary excretion: Does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?

被引:4
作者
Thompson, GA [1 ]
Toothaker, RD [1 ]
机构
[1] Procter & Gamble Pharmaceut, Clin Pharmacol & Pharmacokinet, Hlth Care Res Ctr, Mason, OH 45040 USA
关键词
bioavailability; nonlinear renal clearance; systemic exposure; urinary excretion;
D O I
10.1023/B:PHAM.0000026428.48103.4f
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to assess the influence of nonlinear renal clearance on the ability of urinary excretion data to accurately determine relative differences in systemic exposure and bioavailability. Methods. Serum concentration and urinary excretion-time profiles were simulated assuming an open one-compartmental model with first-order absorption, linear nonrenal clearance, and either linear or nonlinear renal clearance ( saturable secretion). Renal clearance comprised 5% or 95% of total clearance. Doses were varied over a 100-fold range (10-fold decrease/increase from the reference dose). Relative systemic exposures were based on the ratios of AUC and C-max and the corresponding ratios of cumulative amount excreted in urine (A(e)) and the maximum urinary excretion rate. Relative bioavailability was based on the ratios of A(e) and the test to reference dose (D-ratio). Results. When renal clearance was linear and urinary excretion data were used to assess relative systemic exposure and relative bioavailability, no significant errors in accuracy were observed. However, when renal clearance was nonlinear, errors in the accuracy of estimation of relative bioavailability (Cl-r = 5% only) and relative systemic exposure ranged from -53% to +125%; minimal error in accuracy existed in the estimation of relative bioavailability when Clr = 95% (-3% to +6%). Conclusions. Prior to the use of urinary excretion data to assess relative systemic exposure or bioavailability, the relationship between serum concentration and renal clearance should be established.
引用
收藏
页码:781 / 784
页数:4
相关论文
共 28 条
  • [1] Tmax: An unconfounded metric for rate of absorption in single dose bioequivalence studies
    Basson, RP
    Cerimele, BJ
    Desante, KA
    Howey, DC
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (02) : 324 - 328
  • [2] BESSEGHIR K, 1987, RENAL PHYSIOL BIOCH, V10, P221
  • [3] Drug interactions at the renal level - Implications for drug development
    Bonate, PL
    Reith, K
    Weir, S
    [J]. CLINICAL PHARMACOKINETICS, 1998, 34 (05) : 375 - 404
  • [4] Bioavailability and bioequivalence: An FDA regulatory overview
    Chen, ML
    Shah, V
    Patnaik, R
    Adams, W
    Hussain, A
    Conner, D
    Mehta, M
    Malinowski, H
    Lazor, J
    Huang, SM
    Hare, D
    Lesko, L
    Sporn, D
    Williams, R
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (12) : 1645 - 1650
  • [5] AN AREA FUNCTION-METHOD FOR ESTIMATING THE APPARENT ABSORPTION RATE-CONSTANT
    CHENG, HY
    STAUBUS, AE
    SHUM, L
    [J]. PHARMACEUTICAL RESEARCH, 1988, 5 (01) : 57 - 60
  • [6] A RETROSPECTIVE ASSESSMENT OF THE 75/75 RULE IN BIOEQUIVALENCE
    DOBBINS, TW
    THIYAGARAJAN, B
    [J]. STATISTICS IN MEDICINE, 1992, 11 (10) : 1333 - 1342
  • [7] ENDRENYI L, 1991, INT J CLIN PHARM TH, V29, P394
  • [8] Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2003, BIOAV BIOEQ STUD OR
  • [9] *FOOD DRUG ADM, 2003, EXP RES REL STUD DES
  • [10] STUDIES OF THE ORAL BIOAVAILABILITY OF ALENDRONATE
    GERTZ, BJ
    HOLLAND, SH
    KLINE, WF
    MATUSZEWSKI, BK
    FREEMAN, A
    QUAN, H
    LASSETER, KC
    MUCKLOW, JC
    PORRAS, AG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (03) : 288 - 298